|Year : 2020 | Volume
| Issue : 5 | Page : 1025-1033
|Improving Effect of Aminoguanidine on Lipopolysaccharide-Caused Kidney Dysfunction in Rats
Mahmoud Hosseini1, Farimah Beheshti2, Akbar Anaeigoudari3
1 Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2 Neuroscience Research Center; Department of Physiology, School of Paramedical Sciences, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
3 Department of Physiology, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran
Click here for correspondence address and email
|Date of Web Publication||21-Nov-2020|
| Abstract|| |
Kidneys have been shown to be the main target for toxins. Lipopolysaccharide (LPS) is a bacterial endotoxin which can involve in pathogenesis of endotoxemia-caused kidney dysfunction. Excessive production of free radicals such as nitric oxide (NO) and pro-inflammatory cytokines have been reported to contribute in kidney dysfunction. The purpose of this study was to investigate the effect of inducible nitric oxide synthase (iNOS) inhibition against LPS-induced kidney dysfunction in rats. Male rats were assigned into five groups. Control animals were injected saline; LPS group received 1 mg/kg of LPS for five weeks; LPS-AG50, LPS-AG100, and LPS-AG150 groups received AG (50, 100, and 150 mg/kg, respectively) 30 min before LPS. All drugs were administered intraperitoneally. LPS injection enhanced the level of blood urea nitrogen (BUN) and creatinine compared with the control group. Pretreatment with AG resulted in a significant reduction in BUN and creatinine in LPS-AG100 and LPS-AG 150 groups with respect to the LPS group. LPS administration led to a significant increase in interleukin (IL)-6, malondialdehyde (MDA), and NO metabolites as well as a significant decrease in the content of total thiol groups and superoxide dismutase (SOD) and catalase (CAT) activity. Pretreatment with AG reduced the level of IL-6, MDA, and NO metabolites and enhanced the content of total thiol groups and SOD and CAT activity in LPS-AG groups compared to the LPS group. The results of the present study show that inhibition of iNOS has a protective effect against kidney dysfunction caused by LPS.
|How to cite this article:|
Hosseini M, Beheshti F, Anaeigoudari A. Improving Effect of Aminoguanidine on Lipopolysaccharide-Caused Kidney Dysfunction in Rats. Saudi J Kidney Dis Transpl 2020;31:1025-33
|How to cite this URL:|
Hosseini M, Beheshti F, Anaeigoudari A. Improving Effect of Aminoguanidine on Lipopolysaccharide-Caused Kidney Dysfunction in Rats. Saudi J Kidney Dis Transpl [serial online] 2020 [cited 2022 Jan 25];31:1025-33. Available from: https://www.sjkdt.org/text.asp?2020/31/5/1025/301167
| Introduction|| |
Kidneys have been shown to be as a main target for toxins. Endotoxemia, which take place under pathological conditions, including infection plays an important role in kidney injury. It has been reported that lipopolysaccharide (LPS), a bacterial endotoxin, can involve in the pathogenesis of endotoxemia-caused kidney dysfunction. It has been also suggested that kidney dysfunction can associate with overproduction free radicals, reduction glutathione (GSH) levels, and excessive generation of inflammatory cytokines. There are numerous studies confirming the role of LPS in promoting the overproduction of free radicals and pro-inflammatory cytokines., For example, LPS has been revealed to stimulate the excessive generation of nitric oxide (NO) and pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6). In addition, the several signaling pathways, including cyclooxygenase- 2 (COX-2), inducible nitric oxide synthase (iNOS) and nuclear factor κB (NFκB) involve in LPS-stimulated inflammation and oxidative stress., Given these signaling pathways involving in induction inflammatory responses and oxidative stress, the researchers would like to find anti-inflammatory and antioxidant agents that inhibit the overproduction of inflammatory and oxidative damage mediators by LPS.
It has been reported that inhibition of iNOS could be associated with attenuating inflammatory responses and oxidative stress. Amioguanidine (AG), an iNOS inhibitor, has been reported to have anti-inflammatory and antioxidant effects. Scientific evidence show that AG reduces the expression of pro-inflammatory cytokines involved in chronic inflammatory responses including IL-1β and TNF-α., In addition AG has been revealed to protect tissues against oxidative damage by diminishing NO production and enhancing GSH content. Previously in a study, the researchers also suggested that AG can improve cisplatin-caused nephrotoxicity due to its antioxidant properties. Considering these reports, the current study was aimed to study the effect of iNOS inhibition by AG against LPS-induced kidney dysfunction in rat.
| Materials and Methods|| |
The current study was conducted on forty male Wistar rats. The rats were randomly grouped into five groups (n = 8 rats/group) and treated for five weeks as follows: control group was injected with normal saline. LPS group was administered with LPS (1 mg/kg). LPS-AG50, LPS-AG 100, and LPS-AG150 groups were injected with AG (50, 100, and 150 mg/kg, respectively) 30 min before LPS. The animals of the LPS group were administered saline 30 min before LPS instead of AG. Drugs were dissolved in saline and were injected intraperitoneally. All experimental protocols were carried out in accordance with procedures approved by the Committee on Animal Research of Mashhad University of Medical Sciences (Process Number 9000559). LPS (Escherichia coli 055-B5) and AG were purchased from Sigma (Sigma Aldrich Chemical Co.). Other chemicals used to do biochemical assessments were purchased from Merck Company.
Blood sample and kidney tissue collection
At the end of the experimental period (5 weeks), the animals were anesthetized with urethan. Blood samples were collected from the heart and centrifuged at 3500 rpm for 10 min for collection sera. Sera were kept at −80°C until measurement of blood urea nitrogen (BUN) and creatinine. Then the animals were scarified and their kidneys were omitted to measure the IL-6 concentration and biochemical parameters.
Determination of blood urea nitrogen and creatinine
Serum levels of BUN and creatinine were determined by enzymatic colorimetric kits (Pars Azmoon Company, Tehran, Iran) according to the protocol provided by the company.
Determination of interluekin-6
The level of IL-6 in kidney tissue was determined by an ELISA kit (Ebioscience Co., San Diego, CA, USA) in accordance with the manufacturer's protocol.
Determination of oxidative stress parameters in kidney tissue [malondialdehyde, total thiol group (glutathione), nitric oxide, superoxide dismutase and catalase]
Kidney tissue MDA concentration was determined by a spectrophotometric method. In this method, the reaction of MDA with thio-barbituric acid leads to the formation of a colored complex which its peak absorbance is at 535 nm.
GSH content in kidney tissue was evaluated by a spectrophotometric method based on sulfhydryl of GSH reaction with 2,2′-dinitro- 5,5′ dithiodibenzoic acid. Sulfhydryl reaction with 2,2′-dinitro-5,5′ dithiodibenzoic acid produces a yellow colored complex with a peak absorbance at 535 nm.
Level of total nitrite in kidney tissue was estimated by the Griess method. In this method, nitrate was reduced to nitrite, which forms a color appearance with Griess reagent in acidic medium.
Kidney activity of SOD was measured by a spectrophotometric method. The method is based on the autoxidation of pyrogallol which was inhibited by SOD. SOD activity was estimated at 570 nm. One unit of SOD was expressed as the amount of enzyme that inhibits % 50 rate of autoxidation of pyrogallol.
The activity of CAT in kidney tissue was estimated using the Aebi's method. In this method, H2O2 as substrate of CAT is broken into water and oxygen that shows itself on the ultraviolet spectrum as a reduction in the absorbance.
| Statistical Analysis|| |
Results were showed as means ± standard error of mean. Statistical comparison has been carried out by one-way ANOVA followed by Tukey's test. Differences with P <0.05 were considered significant.
| Results|| |
Effect of amioguanidine on kidney function
To determine the protective effect of AG on kidney function, serum levels of BUN and creatinine were measured. LPS administration resulted in a significant increase in the level of BUN and creatinine compared with the control group (P <0.001). AG significantly reduced the serum levels of BUN and creatinine in LPS-AG100 and LPS-AG 150 groups when compared with the LPS group (P <0.01 and <0.001) [Figure 1]a and [Figure 1]b.
|Figure 1: (a and b) Comparison of the serum level of blood urea nitrogen and creatinine between groups. Data are shown as mean ± standard error of mean (n = 8 rats/ group).|
***P <0.001 compared with control group. ++P <0.01 and +++P <0.001 compared with lipopolysaccharide group.
Click here to view
Effect of amioguanidine on concentration of interleukin-6 in kidney tissue
To study the effect of AG on LPS-induced inflammation in the kidney, the level of IL-6 in kidney tissues was measured. As shown in [Figure 2], LPS injection markedly enhanced the IL-6 concentration in LPS- treated animals compared with the control group (P <0.001). Administration of AG before LPS decreased the level of IL-6 in LPS-AG100 and LPS-AG150 groups compared with LPS group (P <0.001).
|Figure 2: Comparison of the interleukin-6 concentration in kidney tissue between groups. Data are shown as mean ± standard error of mean (n = 8 rats/ group).|
***P <0.01 compared with control group. +++P <0.01 compared with lipopolysaccharide group.
Click here to view
Effect of AG on oxidative stress parameters in kidney tissue
In this study, we evaluated the effect of AG on LPS-induced oxidative stress in kidney tissues. LPS caused a significant increase in MDA and NO metabolites concentration as well as a significant decrease in total thiol content in LPS group compared with the control group (P <0.001). Injection of AG significantly decreased MDA and NO metabolites concentration and enhanced the total thion content in LPS-AG100 and LPS-AG150 groups with respect to LPS group (P <0.01 and P <0.001) [Figure 3]a,[Figure 3]b,[Figure 3]c.
|Figure 3: Comparison of the malondialdehyde concentration (a), the total thiol concentration (b) and the level of nitric oxide metabolites (c) in kidney tissue of five groups. Data are presented as Mean ± standard error of mean (n = 8 rat/ group).|
***P <0.001 compared with control group. ++P <0.01 and +++P <0.001 compared with lipopolysaccharide group.
Click here to view
In addition, LPS caused a significant decrease in CAT and SOD activity in LPS group compared with control group (P <0.001). AG-treated rats revealed a significant increase in CAT and SOD activity in LPS-AG100 and LPS-AG 150 groups compared to LPS group (P <0.001) [Figure 4]a and [Figure 4]b.
|Figure 4: Comparison the activity of catalase (a) and superoxide dismutase (b) in kidney tissue between five groups. Data are shown as mean ± standard error of mean (n = 8 in each group).|
***P <0.001 compared with control group and +++ P <0.001 compared with lipopolysaccharide group.
Click here to view
| Discussion|| |
The result of the present study provides evidence to support that inhibition of iNOS by AG attenuates the detrimental effects of LPS on kidney in rat. Endotoxemia has been shown to play a basic role in kidney injury. It has been reported that contamination with bacterial endotoxins such LPS can result in kidney dysfunction. Kidney dysfunction is characterized by a reduction in glomerular filtration rate resulting in an enhancement in serum level BUN and creatinine. In this study, we manifested the effect of LPS administration on kidney function by measuring the serum level of BUN and creatinine in rats. According to the results of the current study, the animals injected with LPS had worse kidney function than untreated animals. This finding was confirmed by increased serum levels of BUN and creatinine in the LPS group when compared with the control group. Based on the previous studies, kidney dysfunction could be a result of the uncontrolled production of pro-inflammatory cytokines. For example nephropathy has been shown to take place after high generation of inflammatory cytokines such as IL-1, IL-6 and IL-33. In addition, some IL-1 family cytokines including IL-33 has been reported to have a basic role in the pathogenesis of some experimental models of kidney damage including kidney ischemia-reperfusion, cisplatin-caused kidney injury and oval bumin-induced nephrotoxicity models. There also are evidence of LPS effect on excessive production of inflammatory cytokines, and free radicals, including NO by immune cells. In addition, the researchers demonstrated the suppression of inflammatory responses by IL-1β inhibitors such as diacerein improved LPS-induced kidney dysfunction in mice through decreasing the level of IL-1β and TNF-α. In line with these reports, in our study, LPS injection resulted in a significant enhancement in the level of IL-6 in kidney tissue in LPS group compared with the control group.
Another cause considered in the pathogenesis of kidney dysfunction is oxidative stress. The harmful effect of lipid peroxidase on the glomerular basement membrane has well been documented. Overproduction of reactive oxygen species and oxidative damage has also been demonstrated to involve in kidney damage in several experimental models such as sepsis, severe burns, toxins, and ischemia reperfusion. In addition, the result of our previous studies determined that LPS administration disturbed oxidative balance through increased concentration of MDA and reduced content of total thiol groups in rat. In present study LPS injection also attenuated oxidative status in kidney tissue. To prove this finding LPS administration resulted in a significant increase in the level of MDA and NO metabolites as well as a significant decrease in content total thiol groups and SOD and CAT activity in kidney tissue in LPS- treated animals with respect to untreated rats.
In this study, we observed that inhibition of iNOS by AG restored the kidney dysfunction caused by LPS in rats. In supporting this claim, the animal treated with AG has better kidney function that those of LPS treated. In this study the serum level of BUN and creatinine in LPS- AG 100 and LPS-AG150 was lower than the LPS group.
It has been proposed that iNOS inhibition could be associated with improving inflammatory status. On the other hand contribution of LPS, IL-1 and TNF-α in induction of iNOS in pathophysiology of some organs such as the liver was documented. AG as an selective inhibitor of iNOS has been shown to have anti-inflammatory effects. Decreased levels of TNF-α, IL-8, and IL-1α by AG have been documented. In addition, it has been indicated that AG ameliorated kidney injury in multiple kidney diseases such as lupus nephropathy, experimental diabetic nephropathy due to its effects in inhibition of inflammatory responses. These findings are in consistence with the results of the current study that reported a decrease in inflammatory responses accompanied with a reduction in the content of IL-6 in AG groups compared to LPS group in kidney tissue.
Researchers also revealed that iNOS expressed in response to bacterial pathogens involve in the overproduction of free radical NO. It was well known that NO could react with other reactive oxygen species such as superoxide, which is associated with oxidative stress. NO has been suggested to have serious harmful effects on various organs due to its effects on overexpression of pro-inflammatory cytokines and induction of oxidative stress. In addition, it has been shown that AG protects tissues against oxidative stress by decreasing NO. AG has been suggested to ameliorate cyclophosphamide – induced oxidative stress in rat. It has been also reported that AG improved nephrotoxicity caused by cisplatin due to its antioxidant properties. In addition, AG has been revealed to have useful effects on radiation-caused lung toxicity via reducing oxidative stress in the rat. In agreement with these findings, in the present study AG administration resulted in a significant reduction in MDA and NO metabolites as well as a significant enhancement in total thiol groups content and CAT and SOD activities in kidney tissue in LPS-AG groups with respect to LPS group. Considering these data, it seems that the ameliorating effect of AG against LPS – induced kidney dysfunction might be mediated due to its useful effects on inflammatory responses and oxidative stress caused by LPS. However, the exact mechanism need to be more studied. In summary, these results showed that iNOS inhibition with AG has a protective effect against kidney dysfunction caused by LPS. According the results of the present study protective effect of AG is likely mediated through decreasing inflammatory responses and oxidative stress induced by LPS.
| Acknowledgments|| |
The authors would like to thank the Vice Presidency of Research of Jiroft University of Medical Sciences for their financial support.
Conflict of interest: None declared.
| References|| |
Abdelsalam M, Elmorsy E, Abdelwahab H, , et al. Urinary biomarkers for early detection of platinum based drugs induced nephrotoxicity. BMC Nephrol 2018;19:219.
Yu G, Liu Q, Dong X, et al. Inhibition of inflammation using diacerein markedly improved renal function in endotoxemic acute kidney injured mice. Cell Mol Biol Lett 2018;23:38.
Xu C, Chang A, Hack BK, Eadon MT, Alper SL, Cunningham PN. TNF-mediated damage to glomerular endothelium is an important determinant of acute kidney injury in sepsis. Kidney Int 2014;85:72-81.
Cachofeiro V, Goicochea M, De Vinuesa SG, Oubiña P, Lahera V, Luño J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease: New strategies to prevent cardiovascular risk in chronic kidney disease. Kidney Int 2008;74: S4-9.
Swarnkar S, Tyagi E, Agrawal R, Singh MP, Nath C. A comparative study on oxidative stress induced by LPS and rotenone in homogenates of rat brain regions. Environ Toxicol Pharmacol 2009;27:219-24.
Lee JW, Lee YK, Yuk DY, et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation 2008;5:37.
Kang MC, Ham YM, Heo SJ, et al. Anti-inflammation effects of 8-oxo-9-octadecenoic acid isolated from Undaria peterseniana in lipopolysaccharide-stimulated macrophage cells. EXCLI J 2018;17:775-83.
Chang CF, Liao KC, Chen CH. 2- Phenylnaphthalene derivatives inhibit lipopolysaccharide-induced pro-inflammatory mediators by downregulating of MAPK/NF-κB pathways in RAW 264.7 macrophage cells. PloS One 2017;12:e0168945.
Beheshti F, Hosseini M, Taheri Sarvtin M, Kamali A, Anaeigoudari A. Protective effect of aminoguanidine against lipopolysaccharide-induced hepatotoxicity and liver dysfunction in rat. Drug Chem Toxicol 2019:1-7.
Díaz A, Rojas K, Espinosa B, et al. Aminoguanidine treatment ameliorates inflammatory responses and memory impairment induced by amyloid-beta 25-35 injection in rats. Neuropeptides 2014;48:153-9.
Mustafa A, Gado AM, Al-Shabanah OA, Al-Bekairi AM. Protective effect of aminoguanidine against paraquat-induced oxidative stress in the lung of mice. Comp Biochem Physiol C Toxicol Pharmacol 2002;132:391-7.
Bostanci MO, Baĝirici F. Neuroprotective effect of aminoguanidine on iron-induced neurotoxicity. Brain Res Bull 2008;76:57-62.
Abraham P, Rabi S, Selvakumar D. Protective effect of aminoguanidine against oxidative stress and bladder injury in cyclophosphamide-induced hemorrhagic cystitis in rat. Redox Rep 2009;27:56-62.
Atasayar S, Gürer-Orhan H, Orhan H, Gürel B, Girgin G, Ozgüneş H. Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats. Exp Toxicol Pathol 2009;61:23-32.
Grinevich V, Knepper MA, Verbalis J, Reyes I, Aguilera G. Acute endotoxemia in rats induces down-regulation of V2 vasopressin receptors and aquaporin-2 content in the kidney medulla. Kidney Int 2004;65:54-62.
Shahbazi S, Alishahi P, Asadpour E. Evaluation of the effect of aminophylline in reducing the incidence of acute kidney injury after cardiac surgery. Anesth Pain Med 2017; 7:e21740.
Oweis AO, Alshelleh SA, Daoud AK, Smadi MM, Alzoubi KH. Inflammatory milieu in contrast-induced nephropathy: A prospective single-center study. Int J Nephrol Renovasc Dis 2018;11:211-5.
Liang H, Xu F, Wen XJ, et al. Interleukin-33 signaling contributes to renal fibrosis following ischemia reperfusion. Eur J Pharmacol 2017;812:18-27.
Chen WY, Tsai TH, Yang JL, Li LC. Therapeutic strategies for targeting IL-33/ST2 signalling for the treatment of inflammatory diseases. Cell Physiol Biochem 2018;49:349- 58.
Park GH, Shinn HK, Kang JH, Na WJ, Kim YH, Park CS. Anti-interleukin-33 reduces ovalbumin-induced nephrotoxicity and expression of kidney injury molecule-1. Int Neurourol J 2016;20:114-21.
Huang C, Li W, Zhang Q, Chen L, Chen W, Zhang H, et al. Anti-inflammatory activities of Guang-Pheretima extract in lipopolysaccharide-stimulated RAW 264.7 murine macrophages. BMC Complement Altern Med 2018;18:46.
Wang Z, Jiang W, Zhang Z, Qian M, Du B. Nitidine chloride inhibits LPS-induced inflammatory cytokines production via MAPK and NF-kappaB pathway in RAW 264.7 cells. J Ethnopharmacol 2012;144:145-50.
Yang G, Lee K, Lee M, Ham I, Choi HY. Inhibition of lipopolysaccharide-induced nitric oxide and prostaglandin E2 production by chloroform fraction of Cudrania tricuspidata in RAW 264.7 macrophages. BMC Complement Altern Med 2012;12:250.
Zhang R, Yu Y, Deng J, et al. Sesamin ameliorates high-fat diet-induced dyslipidemia and kidney injury by reducing oxidative stress. Nutrients 2016;8:
Mittwede PN, Xiang L, Lu S, Clemmer JS, Hester RL. Oxidative stress contributes to orthopedic trauma-induced acute kidney injury in obese rats. Am J Physiol Renal Physiol 2015;308:F157-63.
Hosseini M, Anaeigoudari A, Beheshti F, Soukhtanloo M, Nosratabadi R. Protective effect against brain tissues oxidative damage as a possible mechanism for beneficial effects of L-arginine on lipopolysaccharide induced memory impairment in rats. Drug Chem Toxicol 2018;41:175-81.
Hafez HM, Ibrahim MA, Ibrahim SA, Amin EF, Goma W, Abdelrahman AM. Potential protective effect of etanercept and aminoguanidine in methotrexate-induced hepatotoxicity and nephrotoxicity in rats. Eur J Pharmacol 2015;768:1-2.
Jiang WW, Kong LB, Li GQ, Wang XH. Expression of iNOS in early injury in a rat model of small-for-size liver transplantation. Hepatobiliary Pancreat Dis Int 2009;8:146-51.
Nakamura H, Tsukada H, Oya M, et al. Aminoguanidine has both an anti-inflammatory effect on experimental colitis and a proliferative effect on colonic mucosal cells. Scand J Gastroenterol 1999;34:1117-22.
Tian M, Qing C, Niu Y, et al. Aminoguanidine cream ameliorates skin tissue microenvironment in diabetic rats. Arch Med Sci 2016; 12:179-87.
Fujihara CK, Mattar AL, Vieira JM Jr, et al. Evidence for the existence of two distinct functions for the inducible NO synthase in the rat kidney: Effect of aminoguanidine in rats with 5/6 ablation. J Am Soc Nephrol 2002;13: 2278-87.
Chakravortty D, Hensel M. Inducible nitric oxide synthase and control of intracellular bacterial pathogens. Microbes Infect 2003;5: 621-7.
Kröncke KD, Fehsel K, Suschek C, Kolb-Bachofen V. Inducible nitric oxide synthase-derived nitric oxide in gene regulation, cell death and cell survival. Int Immunopharmacol 2001;1:1407-20.
Hung CR. Role of gastric oxidative stress and nitric oxide in formation of hemorrhagic erosion in rats with ischemic brain. World J Gastroenterol 2006;12:574-81.
Eroglu C, Yildiz OG, Saraymen R, Soyuer S, Kilic E, Ozcan S. Aminoguanidine ameliorates radiation-induced oxidative lung damage in rats. Clin Invest Med 2008;31:E182-8.
Department of Physiology, School of Medicine, Jiroft University of Medical Sciences, Jiroft
[Figure 1], [Figure 2], [Figure 3], [Figure 4]
|This article has been cited by|
||Ameliorative role of inducible nitric oxide synthase inhibitors against sodium arsenite-induced renal and hepatic dysfunction in rats
| ||Ashwani Kumar Sharma, Anmoldeep Kaur, Tajpreet Kaur, Sarabjit Kaur, Devendra Pathak, Amrit Pal Singh |
| ||Drug and Chemical Toxicology. 2021; : 1 |
|[Pubmed] | [DOI]|
| Article Access Statistics|
| Viewed||874 |
| Printed||14 |
| Emailed||0 |
| PDF Downloaded||154 |
| Comments ||[Add] |
| Cited by others ||1 |